LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, announced its participation in the BTIG 4th Annual Ophthalmology Day. CEO Nick Curtis will engage in a fireside chat on December 2, 2024, at 2 p.m. ET. The company's management team will also conduct one-on-one meetings with institutional investors. The event is exclusively for current and prospective BTIG clients, who must contact their BTIG representative to access the live event.
LENSAR (Nasdaq: LNSR), un'azienda globale di tecnologia medica specializzata in soluzioni laser robotiche per il trattamento della cataratta, ha annunciato la sua partecipazione al BTIG 4° Annuale Giorno dell'Oftalmologia. Il CEO Nick Curtis parteciperà a una chiacchierata informale il 2 dicembre 2024, alle 14:00 ET. Il team di gestione dell'azienda condurrà anche incontri individuali con investitori istituzionali. L'evento è esclusivamente per i clienti attuali e potenziali di BTIG, che devono contattare il proprio rappresentante BTIG per accedere all'evento dal vivo.
LENSAR (Nasdaq: LNSR), una empresa global de tecnología médica especializada en soluciones láser robóticas para el tratamiento de cataratas, anunció su participación en el BTIG 4° Día Anual de Oftalmología. El CEO Nick Curtis participará en una charla informal el 2 de diciembre de 2024, a las 2 p.m. ET. El equipo de gestión de la empresa también realizará reuniones individuales con inversores institucionales. El evento es exclusivamente para clientes actuales y potenciales de BTIG, quienes deben contactar a su representante de BTIG para acceder al evento en vivo.
LENSAR (Nasdaq: LNSR)는 백내장 치료를 위한 로봇 레이저 솔루션을 전문으로 하는 글로벌 의료 기술 회사로, BTIG 제4회 연례 안과의 날에 참여할 것이라고 발표했습니다. CEO 닉 커티스는 2024년 12월 2일 오후 2시 ET에 편안한 대담에 참여할 예정입니다. 회사의 경영진도 기관 투자자들과 개별 미팅을 진행할 것입니다. 이 이벤트는 현재 및 잠재적인 BTIG 고객 전용으로, 라이브 이벤트에 접근하려면 BTIG 담당자에게 연락해야 합니다.
LENSAR (Nasdaq: LNSR), une entreprise mondiale de technologie médicale spécialisée dans les solutions laser robotiques pour le traitement de la cataracte, a annoncé sa participation au BTIG 4ème journée annuelle d'ophtalmologie. Le PDG Nick Curtis participera à une conversation informelle le 2 décembre 2024 à 14h00 ET. L'équipe de direction de l'entreprise organisera également des réunions individuelles avec des investisseurs institutionnels. L'événement est exclusivement réservé aux clients actuels et potentiels de BTIG, qui doivent contacter leur représentant BTIG pour accéder à l'événement en direct.
LENSAR (Nasdaq: LNSR), ein globales Medizintechnikunternehmen, das auf robotergestützte Laserlösungen zur Behandlung von Katarakten spezialisiert ist, gab seine Teilnahme am BTIG 4. jährlichen Tage der Augenheilkunde bekannt. CEO Nick Curtis wird am 2. Dezember 2024 um 14:00 Uhr ET an einem Gespräch teilnehmen. Das Management-Team des Unternehmens wird auch individuelle Treffen mit institutionellen Investoren abhalten. Die Veranstaltung ist ausschließlich für aktuelle und potenzielle BTIG-Kunden, die ihren BTIG-Vertreter kontaktieren müssen, um Zugang zur Live-Veranstaltung zu erhalten.
- None.
- None.
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
When is LENSAR (LNSR) presenting at the BTIG Ophthalmology Day 2024?
What type of presentation will LENSAR (LNSR) give at the BTIG Ophthalmology Day?
Who can attend LENSAR's (LNSR) presentation at the BTIG Ophthalmology Day?
Will LENSAR (LNSR) management be available for investor meetings at the BTIG event?
